Literature DB >> 11926004

The Lys-76-Thr mutation in PfCRT and chloroquine resistance in Plasmodium falciparum isolates from Uganda.

J Kyosiimire-Lugemwa1, A J Nalunkuma-Kazibwe, G Mujuzi, H Mulindwa, A Talisuna, T G Egwang.   

Abstract

Recent molecular studies of chloroquine (CQ) resistance of Plasmodium falciparum have demonstrated an association between a mutation in the PfCRT gene and CQ resistance. We identified wild type and mutant alleles of the PfCRT codon 76 in baseline pre-CQ treatment P. falciparum isolates collected during 1999 and investigated their relationship to CQ efficacy in 3 different sites with different levels of CQ parasite resistance in Uganda. Of 32 isolates from Mulago Hospital, all were mutant (100%), while of 45 isolates from Tororo, 5 (11%) were mixed wild type and mutant and 40 (89%) were mutants only. Of 41 isolates from Apac, 13 (32%) were mixed wild type and mutant whereas 28 (68%) were mutants only. The finding of 100% prevalence of the Thr-76 mutant allele in all isolates at the 3 sites was remarkable. We found no association between the presence of Thr-76 mutation and treatment outcome at all the sites. However, the prevalence of the wild-type Lys-76 allele was higher in Apac, an area with lower CQ parasite resistance, compared to Tororo and Mulago which have relatively higher CQ parasite resistance. The Thr-76 allele as a marker of CQ resistance is probably useful in regions where the allele frequency has not yet plateaued.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11926004     DOI: 10.1016/s0035-9203(02)90252-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  8 in total

Review 1.  History, dynamics, and public health importance of malaria parasite resistance.

Authors:  Ambrose O Talisuna; Peter Bloland; Umberto D'Alessandro
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

2.  Prevalence of Plasmodium falciparum pfcrt polymorphisms and in vitro chloroquine sensitivity in Senegal.

Authors:  J P Daily; C Roberts; S M Thomas; O Ndir; T Dieng; S Mboup; D F Wirth
Journal:  Parasitology       Date:  2003-05       Impact factor: 3.234

3.  Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda.

Authors:  George W Mbogo; Sheila Nankoberanyi; Stephen Tukwasibwe; Frederick N Baliraine; Samuel L Nsobya; Melissa D Conrad; Emmanuel Arinaitwe; Moses Kamya; Jordan Tappero; Sarah G Staedke; Grant Dorsey; Bryan Greenhouse; Philip J Rosenthal
Journal:  Am J Trop Med Hyg       Date:  2014-05-05       Impact factor: 2.345

4.  First evidence of pfcrt mutant Plasmodium falciparum in Madagascar.

Authors:  Milijaona Randrianarivelojosia; David A Fidock; Olivier Belmonte; Stephanie G Valderramos; Odile Mercereau-Puijalon; Frédéric Ariey
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-01-26       Impact factor: 2.184

5.  In vivo and in vitro analysis of chloroquine resistance in Plasmodium falciparum isolates from Senegal.

Authors:  Ousmane Sarr; Alissa Myrick; Johanna Daily; Bernard M Diop; Therese Dieng; Omar Ndir; Pape Salif Sow; Souleymane Mboup; Dyann F Wirth
Journal:  Parasitol Res       Date:  2005-06-29       Impact factor: 2.289

6.  Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data.

Authors:  Anne E P Frosch; Meera Venkatesan; Miriam K Laufer
Journal:  Malar J       Date:  2011-05-09       Impact factor: 2.979

7.  Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications.

Authors:  Reem A Mubjer; Ahmed A Adeel; Michael L Chance; Amir A Hassan
Journal:  Malar J       Date:  2011-08-21       Impact factor: 2.979

8.  The detection of pfcrt and pfmdr1 point mutations as molecular markers of chloroquine drug resistance, Pahang, Malaysia.

Authors:  Wahib M Atroosh; Hesham M Al-Mekhlafi; Mohammed A K Mahdy; Johari Surin
Journal:  Malar J       Date:  2012-08-01       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.